Category Archives: Press Releases

CollabRx Announces Pricing Of Public Offering Of Approximately $4,800,000 Of Common Stock And Warrants

SAN FRANCISCO, Feb. 19, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX) today announced the pricing of an underwritten public offering of 3,840,000 shares of its common stock and warrants to purchase up to an aggregate of 3,840,000 shares of its common stock at an offering price of $1.25 per common share and $0.0001 per warrant. […]

CollabRx Announces Pricing Of Public Offering Of Approximately $3,000,000 Of Common Stock

SAN FRANCISCO, Feb. 25, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (Nasdaq:CLRX) today announced the pricing of an underwritten public offering of 2,362,205 shares of its common stock at a price to the public of $1.27 per share. Gross proceeds to CollabRx from this offering are approximately $3,000,000 before deducting underwriting discounts and commissions and other […]

CollabRx and Medytox Solutions Sign Definitive Merger Agreement

Combination Will Create New Generation Healthcare Company  SAN FRANCISCO, CA and WEST PALM BEACH, FL – April 16, 2015 — CollabRx, Inc. (NASDAQ:CLRX) (“CollabRx”) and Medytox Solutions, Inc. (OTCQB: MMMS) (“Medytox”) today announced that they have entered into a definitive merger agreement. Closing of the merger is subject to, among other things, gaining stockholder approvals from […]

CollabRx Receives Notice from Nasdaq on Change of Control

Company Reconfirms Intent to Remain on Nasdaq San Francisco, CA – April 29, 2015 – CollabRx, Inc. (NASDAQ: CLRX) (“CollabRx” or “the Company”), today announced that it had received notice from The NASDAQ Stock Market LLC (“Nasdaq”) that the Company’s proposed transaction with Medytox Solutions, Inc. (OTCQB: MMMS) (“Medytox”) when completed would constitute a business combination […]

CollabRx Announces Receipt of NASDAQ Notice of Noncompliance for Bid Price

San Francisco, CA – June 5, 2015 – CollabRx, Inc. (NASDAQ: CLRX) (herein “CLRX” or “the Company”), announced today that it received a letter from The NASDAQ Stock Market LLC (“Nasdaq”) stating that the bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share […]

COLLABRX ANNOUNCES SPECIAL MEETING OF ITS STOCKHOLDERS TO BE HELD OCTOBER 28, 2015

SAN FRANCISCO, CA – September 24, 2015 – CollabRx, Inc. (“CollabRx”) (NASDAQ: CLRX) today announced that the registration statement on Form S-4 and the definitive joint proxy statement/prospectus contained therein, regarding CollabRx’s proposed merger with Medytox Solutions, Inc. (“Medytox”) (OTCQB: MMMS), has been declared effective by the Securities and Exchange Commission (the “SEC”). CollabRx will hold […]

COLLABRX STOCKHOLDER SPECIAL MEETING TO BE HELD OCTOBER 28, 2015

SAN FRANCISCO, CA – October 22, 2015 – As previously announced,CollabRx, Inc. (“CollabRx”) (NASDAQ: CLRX) will hold a special meeting of its stockholders on Wednesday, October 28, 2015, to consider and act on several proposals recommended by CollabRx’s board and management regarding its proposed merger with Medytox Solutions, Inc. (“Medytox”) (OTCQB: MMMS). The registration statement on Form […]

CollabRx Stockholders Approve Merger With Medytox Solutions

SAN FRANCISCO, Oct. 30, 2015 (GLOBE NEWSWIRE) — CollabRx, Inc. (“CollabRx”) (NASDAQ:CLRX) announced today it held its Special Meeting of Stockholders to approve the following proposals: (1) the issuance of shares of CollabRx common stock and other securities exercisable or convertible for shares of CollabRx common stock in connection with the proposed merger with Medytox […]

CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016

Dr. George Lundberg and panelists to discuss Practicing Pathologists in Personalized Medicine SAN FRANCISCO, CA – December 10,  2015 – CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ: RNVA) today announced that its Chief Medical Officer, George Lundberg, MD, will chair this year’s Personalized Medicine World Conference, Silicon Valley session titled, “The […]

CollabRx Announces Adrienne Craig-Kennard as Vice President of Global Business Development and Strategic Alliances

Veteran International Business Development Executive to Lead Organization’s Growth Efforts SAN FRANCISCO, Jan. 19, 2016 (GLOBE NEWSWIRE) – CollabRx, Inc., a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ:RNVA) today announced Adrienne Craig-Kennard will serve as Vice President of Global Business Development and Strategic Alliances. Craig-Kennard, an expert in international business development […]